Abstract: PKB/AKT constitutes an important pathway that regulates the signaling of multiple essential biological processes. PTEN is a dual protein/lipid phosphatase whose main substrate is phosphatidyl-inositol,3,4,5 triphosphate (PIP3), the product of PI3K. Increases in PIP3 result in the recruitment of PDK1 and AKT to the membrane where they are activated. Furthermore, PI3K can be activated by direct binding to oncogenic Ras proteins. Many components of this pathway have been described as genetically altered in cancer. PTEN activity is lost by mutations, deletions or promoter methylation at high frequency in many primary and metastatic human cancers, and some germline mutations of PTEN are found in several familial cancer predisposition syndromes. Activating mutations of PI3K occur in human tumors and confer tumorigenic properties to cells in culture. Taken together, this evidence indicates that the AKT pathway is a promising potential target for cancer chemotherapy. Indeed, many companies and academic laboratories have initiated a variety of approaches to inhibit the pathway at different points. Essentially, PI3Ks, PDK1, AKT and mTOR are heavily targeted for therapy in different ways. These proteins are kinases, which are very "druggable" targets a priori, and, according to the "addiction hypothesis", cancer cells with the activated pathway will be more dependent on its activity for their survival.
induced by a number of stimuli including growth factor withdrawal, detachment of extracellular matrix components, UV irradiation, cell cycle discordance and activation of FAS signaling [4, 5, 8] , is suppressed by activation of AKT. Hyperactivated AKT has also been shown to promote cell proliferation, cell growth and metabolism, migration [5] and resistance to hypoxia [9] (See below).
Different genetic approaches have been used to directly assess the role of AKT in PTEN null-induced phenotypes. Deletion of AKT1 reversed the survival phenotype in PTEN-null cells and abrogated their growth advantage [10] . Furthermore, deleting both alleles of AKT1 appears to have additional effects, since mutated cells were more sensitive to serum starvation-induced cell death. AKT1 knockout (KO) cells lose the ability to compete with wildtype or PTEN-null cells [10] . Similarly, inactivation of AKT by dominant-negative mutations inhibits the survival advantage provided by activated Class I PI3K [11] . These and other results underscore the essential role of AKT in the PTEN/PI3K pathway [12] [13] [14] [15] [16] .
PI3K may control multiple pathways (PIP3-dependent orindependent) other than the AKT pathway. PIP3-dependent functions, not related to AKT, may be PDK1 dependent as suggested by hypomorphic PDK1 mice [17] . Reduced levels of PDK1 expression in PTEN(+/-) mice markedly protect these animals from developing a wide range of tumors. PDK1 has been shown to phosphorylate a critical residue in activation loops of all AGC kinase family members including AKTs [18] [19] [20] [21] [22] [23] , SGKs [24, 25] , S6K [19, 26] , PKA [27] , PKC [28] [29] [30] , RSK [31] , and protein kinase N [32, 33] . Furthermore, other proteins might also be recruited and activated by increases in PIP3 [5, 34] . The PH domain was the first phosphoinositide-binding domain identified. It is present in the largest number of proteins and is associated with formation of signaling complexes on the plasma membrane. Recent studies have identified other novel phosphoinositide-binding domains (Fab1p, YOTB, Vps27p, EEA1, Phox homology and epsin N-terminal homology (ENTH)), extending the functional versatility of the pathway (Fig.  (2) ).
AKT might also be regulated by non-canonical pathways. DNA-PK regulates AKT1 by S473 phosphorylation following detection of double strands breaks in DNA. AKT then provides a prosurvival signal for the cell by affecting DNA-induced transcription [35, 36] . This AKT1 activation is dependent on PDK1 activity; once phosphorylated, AKT localizes to the nucleus adjacent to DNA-double strand breaks where it interacts with DNA-PK. Additionally, AKT activation may be induced by calcium signaling [37, 38] . AKT phosphorylation is inhibited by calmodulin inhibitors and induced by calcium agonists [38] .
RAS
Activating point mutations in the genes encoding the Ras subfamily of small GTP-binding proteins contribute to the formation of a large proportion of human tumors [39] . The expression of this active version of Ras promotes tumor initiation by activating at least three different effectors: Raf, PI3K, and RalGEFs [40] [41] [42] [43] [44] . Raf is a serine/threonine kinase that can translocate to the plasma membrane from the cytoplasm and be activated by GTP-Ras. Activated Raf proteins then initiate a MAP kinase (MAPK) signal transduction cascade leading to transformed phenotypes, anchorage-independent growth, and angiogenesis [43, 45] . Finally, RalGEFs, a family of guanine exchange factors, are activated via their recruitment to the plasma membrane by GTP-Ras [46] . In human cells, the Ras effector pathways MAPK, RalGEF, and PI3K are reported as required to initiate tumor growth [47] [48] [49] [50] . Conversely, activation of the PI3K/AKT pathway can substitute for Ras once tumors are formed, although other effectors were still activated independently of Ras, presumably by factors provided upon the establishment of the tumor microenvironment. Thus, as tumorigenesis progresses, the addiction of cancers to their initiating oncogene is reduced to, at least in the case of Ras, the PI3K/AKT pathway [50] .
AKT "MASTER" KINASE
Membrane localization appears to be critical for AKT activation. Modifications that target AKT to the membrane, such as the gag sequence found in v-Akt or fusion of a myristoylation sequence from Src-like kinases to the amino terminus of AKT, result in constitutive activation of the kinase [51] [52] [53] .
AKT phosphorylates proteins containing the amino acid sequence RXRXXS/T-B [54] (X represent any amino acid and B is any bulky hydrophobic residue). At the time of this writing, more than 100 non-redundant AKT substrates have been reported, and many of them do not contain the canonical AKT recognition motif [55] . This diversity of substrates elicits a broad physiological response mediated by multiple downstream effectors (Fig. (1) ). The three AKT isoforms are very similar, and it is unclear whether they have distinguishable substrate specificities. However, knockout mice have revealed distinct physiological functions for the three AKT isoforms [56, 57] . Although combined knockouts have demonstrated that functional redundancy exists between the three isoforms, the distinct phenotypes resulting from individual AKT loss suggest that there are likely to be functional differences between isoforms at the cellular level.
AKT enhances cell survival by blocking the function of proapoptotic proteins. AKT negatively regulates the function or expression of several proapoptotic proteins that inactivate prosurvival Bcl-2 family members. Survival factors stimulate AKTmediated phosphorylation of BAD, and this creates a binding site for 14-3-3 proteins, which sequester BAD from its target proteins [58] . AKT also inhibits the expression of BIM through effects on transcription factors such as FOXO and p53 [59] . AKT phosphorylates the FOXO family members FOXO, FOXO3a and FOXO4 [60] while they are nuclear, creating a binding site for 14-3-3 proteins, which then triggers their export from the nucleus. By this mechanism, AKT blocks FOXO-mediated transcription of target genes that promote apoptosis, cell-cycle arrest, and metabolic processes. AKT also promotes survival by phosphorylating MDM2, an E3 ubiquitin ligase that accelerates p53 degradation. AKT phosphorylates MDM2, promoting translocation of MDM2 to the nucleus where it negatively regulates p53 function [61] [62] [63] . Two transcriptional targets of p53, Puma and Noxa proteins, appear to be essential in p53-induced apoptosis [64] . Likewise, AKT has also been found to phosphorylate S196 on human procaspase-9, which is correlated with a decrease in the protease activity of caspase-9 in vitro [65] . Additionally, AKT exerts some of its cell-survival effects through the modification of nutrient uptake and metabolism (reviewed in [8, 66] ).
One of the best-conserved functions of AKT is its role in cell mass increase through activation of the mTOR complex 1 (mTORC1 or the mTOR-raptor complex), which is regulated by both nutrients and growth factor signaling. mTORC1 is a critical regulator of translation initiation and ribosome biogenesis and plays an evolutionarily conserved role in cell growth control [67] . The enhanced sensitivity of cancer cells with hyperactive PI3K/AKT to mTORC1 inhibitors illustrates the importance of mTORC1 activation downstream of AKT [68] . AKT activates mTORC1 indirectly by inhibiting TSC2, thereby allowing Rheb-GTP to activate mTORC1 signaling. Recently, AKT was shown to directly phosphorylate PRAS40 [69] , an event important for 14-3-3 binding. PRAS40 associates with and negatively regulates mTORC1 signaling [70] .
AKT activation can stimulate proliferation through multiple downstream targets impinging on cell-cycle regulation. AKT phosphorylates the cyclin-dependent kinase inhibitors p21Cip1/WAF1 and p27Kip1, promoting their cytosolic localization [62, [71] [72] [73] and preventing their cell-cycle inhibitory effects. AKT-dependent phosphorylation of other targets such as GSK3, TSC2, and PRAS40 is also likely to drive cell proliferation through regulation of stability and synthesis of proteins involved in cell-cycle entry.
In response to growth factors, AKT signaling regulates nutrient uptake and metabolism. One of the most important physiological functions of AKT is to stimulate glucose uptake in response to insulin. Akt2, the primary isoform expressed in insulin-responsive tissues, has been found to associate with glucose transporter 4 (Glut4)-containing vesicles upon insulin stimulation of adipocytes [74] , and AKT activation leads to Glut4 plasma membrane translocation [75] . AKT activation can enhance the rate of glycolysis by promoting expression of glycolytic enzymes through HIF [76, 77] . In a cell-context-dependent manner, AKT-mediated phosphorylation and inhibition of FOXO1 also contribute to glucose homeostasis (reviewed in [78] ). Furthermore, AKT plays important roles in both physiological and pathological angiogenesis through its effects on both endothelial cells and cells producing angiogenic signals, such as tumor cells. The PI3K-AKT pathway is robustly activated by vascular endothelial growth factor (VEGF; reviewed in [79] ), promoting endothelial cell survival, growth, and proliferation.
The AKT pathway is highly connected with other pathways. AKT signaling can activate the NF-B transcription factor by direct phosphorylation of I B kinase (IKK ), thereby leading to activation of the kinase upstream of NF-B [80] . AKT can also directly phosphorylate c-Raf leading to an inhibitory effect on the MAPK pathway [81] .
AKT-INDEPENDENT PATHWAYS
Loss of PTEN function results in constitutive activation of AKT that plays a key role in PTEN-mediated tumorigenesis via multiple mechanisms [5, 8, 34, 61, [82] [83] [84] [85] . However, there are alternative mechanisms of PTEN-mediated tumorigenesis, which are possibly AKT-independent [86] [87] [88] [89] . PTEN has been shown to directly associate with p53-increasing its stability, protein levels, and transcriptional activity. Pten +/ ;p53 +/ double heterozygous mice show an onset of lymphoma development similar to that seen in p53 / animals. p53 protein levels are dramatically reduced in Pten / cells due to PTEN mediated stabilization of p53, which increases its half-life. Furthermore, ectopic expression of PTEN phosphatase-dead mutants also leads to a significant increase in p53 protein levels. PTEN can stabilize p53 even in the absence of MDM2, suggesting that PTEN can regulate p53 levels in a phosphatase-independent and MDM2-independent manner (Fig.  (2) ). Moreover, PTEN physically associates with endogenous p53 and regulates the transcriptional activity of p53 by modulating its DNA binding capability [88] .
PTEN contains a sequence motif that is highly conserved among the protein tyrosine phosphatase family members. PTEN has been also shown to possess phosphatase activity on phosphotyrosyl and phosphothreonyl-containing substrates [90] [91] [92] in vitro and on phosphatidylinositol (3, 4, 5) trisphosphate, the product of phosphatidylinositol 3-kinase (PI3K), both in vitro and in vivo [1, [92] [93] [94] . The fact that naturally occurring mutations in the PTEN phosphatase domain (such as PTEN-C124S and PTEN-G129E mutants) are tumorigenic indicates that the effects of PTEN's phosphatase-independent activity in tumorigenesis may be tissuespecific or associated with a more aggressive phenotype upon loss of PTEN function. PTEN regulates cell cycle arrest via protein phosphatase-dependent interaction with cyclin D. The oncogenic potential of PTEN is further highlighted by its role in integrin signaling and its ability to dephosphorylate focal adhesion kinases that reduce cell adhesion and enhance migration [95] [96] [97] . PTEN appears to inhibit cell cycle progression through cooperation of its protein phosphatase activity, which leads to down-regulation of cyclin D1, and its lipid phosphatase activity, which leads to upregulation of p27kip1 [82] . PTEN also abrogates insulin-stimulated ETS2 activation independently of PI3K, likely through protein phosphatase activity [86] . ETS transforms NIH3T3 cells, allowing these to become tumorigenic in mice. Inhibition of ETS2 can inhibit ras-dependent transformation and abolish anchorage-independent growth and migration of breast carcinoma cells. Furthermore, ETS2 can also activate the cyclin D1 promoter.
PTEN is also found in the nucleus [98, 99] . Nuclear localization of PTEN may contribute to its tumor suppressor activity in several ways. It is possible that PTEN is a nuclear PIP3 phosphatase, although it has been suggested that nuclear PTEN does not dephosphorylate the nuclear pool of PIP3 [100] . The protein phosphatase functions of nuclear PTEN in the downregulation of MAPK and cyclin D1 activity have been implicated in G1 cell cycle arrest. Regulation of p53 activity and stability by direct protein-protein interaction also occurs within the nucleus [89, 101] (Fig. (2) ).
Recently, another nuclear tumor suppressor activity of PTEN has been reported. PTEN loss increased genomic instability by causing AKT-mediated sequestration of Chk1 and compromising the DNA-damage response [102] . Nuclear PTEN co-localized with centromeres, binding to Cenp-C, which is required for proper kinetochore assembly and for metaphase to anaphase transition. The C-terminus, but not the phosphatase domain of PTEN, was required for this function [103] . Therefore, PTEN-null MEFs contain an increased number or chromosomal abnormalities [103] . These chromosomal aberrations suggest a possible defect in the DNAdamage checkpoint. Furthermore, PTEN was bound to the Rad51 promoter, suggesting a more direct impact of PTEN on transcriptional regulation [103] . Although it does not directly activate the transcription of Rad51, PTEN enhances E2F-mediated transactivation. Other studies have also revealed PTEN interacts with PCAF and p300, transcriptional coactivators that function as histone acetyltransferases [89, 104] .
PTEN/PI3K/AKT IN TUMORS
The PTEN/PI3K pathway is highly involved in cancer. PTEN activity is lost by mutations, deletions or promoter methylation silencing at high frequency in many primary and metastatic human cancers [6, 105] (Fig. (3) ). Germ line mutations of PTEN are found in Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome and a Proteus-like syndrome, all of them familial cancer predisposition syndromes [106] [107] [108] [109] . Recently, many activating mutations have been described in the PI3KCA gene (coding for the p110 catalytic subunit of PI3K) found in human tumors [105, 110] . The three most frequently observed PI3-kinase mutations, E542K, E545K, and H1047R, showed enhanced catalytic activity [111] , comparable to membrane bound myr-p110. They are able to constitutively activate AKT and activate transcription. These enhanced biochemical capabilities translate to enhanced oncogenic activity of PI3K mutants [112, 113] . Oncogenic mutations have only been detected in the PI3KCA gene (p110 isoform), despite observations that the activation, by membrane tagging, of all the class I PI3K isoforms has oncogenic potential [11, 112, 113] .
Carpten et al. [114] reported a somatic mutation in human breast, colorectal and ovarian cancers that results in a glutamic acid to lysine substitution at amino acid 17 (E17K) in the lipid-binding pocket of AKT1. Lys 17 alters the electrostatic interactions of the pocket and forms new hydrogen bonds with a phosphoinositide ligand. Furthermore, this mutation activates AKT1 by means of pathological localization to the plasma membrane, stimulates downstream signaling, transforms cells and induces leukemia in mice. This mechanism indicates a direct role of AKT1 in human cancer and adds to the known genetic alterations that promote oncogenesis through the phosphatidylinositol-3-OH kinase/AKT pathway [114] . The AKT-E17K mutation does not change AKT's sensitivity to ATP-competitive inhibitors, but it does change its sensitivity to allosteric inhibitors. Therefore, mutation status will have to be considered before AKT allosteric inhibitors are prescribed as therapies for individual patients.
Activation without mutations of PI3K and AKT is reported to occur in breast [115] [116] [117] , ovarian [116, 118, 119] , pancreatic [120] , esophageal [121] , thyroid [122] and other cancers [105, 123] . Interestingly, several other genes of the pathway can act as tumor suppressors, including TSC1, TSC2, and LKB1, which carry germ line familial mutations, FOXO proteins and likely the phosphatases PHLPP and SHIP.
PTEN/PI3K/AKT GENETICS
Transgenic studies reveal that although PTEN knockout is embryonic lethal, heterozygous mice develop tumors in several organs [124] [125] [126] [127] [128] . Moreover, heterozygous PTEN mice crossed with MMTV-wnt1 transgenic mice develop mammary tumors earlier in life than parental strains [129] . In conditional models, PTEN loss resulted in the generation of tissue-specific tumors. Elimination of PTEN specifically in the mammary gland induces excessive side branching, accelerated ductal extension and mammary tumors with metastatic properties. [130, 131] . Similar tumorigenic properties have been observed in other tissues after PTEN conditional excision [132] [133] [134] [135] [136] . In these models, conditional PTEN depletion also resulted in developmental defects, highlighting the importance of PTEN in normal differentiation.
Despite the proposed relevance of AKT in the PTEN pathway, no findings comparable to those summarized above have been observed when AKT is activated in transgenic models. At least four independent groups have generated transgenic mice expressing constitutively active AKT in the mammary gland under the control of the MMTV promoter [9, [137] [138] [139] [140] . Targeted mammary expression of polyoma middle T antigen elicits multifocal metastatic mammary tumors in mice [141] . However, the same antigen depleted of its capability to activate PI3K only induces mammary hyperplasia with a high apoptotic index. The complementation of this defective polyoma middle T antigen with active AKT restored the accelerated rate of tumorigenesis [138] . In another model, AKT1 ablation inhibits, whereas AKT2 accelerates, development of adenocarcinomas induced by Erb2/neu in the mammary gland [142] . Interestingly, activated AKT accelerated mammary tumors [143] but inhibited lung metastasis in erb2 transgenic mice, providing longer life expectancy in these mice.
The three isoforms of AKT have been targeted by homologous recombination in individual or combined knock-outs. AKT1-null mice die shortly after birth because of growth retardation due to defects in placental development [144, 145] . Tissue-targeted deletion of AKT1 illustrates its important role in regulating cell growth and cell size [145] [146] [147] . AKT-null mice present with significant defects in lactation resulting from failure to up-regulate glucose uptake, aberrant lipid synthesis and inappropriate regulation of the enzymes involved in -oxidation of fatty acids [148] . AKT2-null mice develop insulin resistance and a type II diabeteslike syndrome [149, 150] . AKT3 plays an essential role in postnatal brain development [151, 152] . Double AKT1/AKT2 null mice die after birth and exhibit dwarfism and defects in adipogenesis, skin, muscle and bone development [153] . Double AKT2/3 KO mice are viable and fertile, while the absence of AKT1/3 is embryonic lethal due to severe cardiovascular and nervous system defects [147, 153] .
The situation with PI3K is more complicated [154] . Mouse models with inducible activating mutations of PI3KCA (p110 -1047 ) in lung have been reported to produce lung adenocarcinomas. These tumors revert upon cessation of transgenic PI3K-1047H expression [155] . We have targeted p110 to the membrane activating PI3K in transgenic mice [156, 157] . These mice are prone to spontaneous neoplasias, and PI3K inhibition by LY294002 was found to reduce AKT pathway activation (Fig. (4) ). P110 and p110 null mice are embryonic lethal, as well as homozygous kinase death p110 mutant knock-in mice [158] [159] [160] . Mice heterozygous for this mutation were viable and fertile but had severe defects in the insulin pathway. These defects led to reduced growth, hyperinsulinemia, glucose intolerance and increased adiposity, which, however, did not progress to diabetes [159] . Conversely, MEFs from p110 -/-mice can be grown and studied. In these MEFs, p110 is essential for proper growth factor signaling and oncogenic transformation [169] . p110 , although not essential, plays a critical role in regulating the immune system [161] . The genetic proof of PI3K pathway relevance in ras-induced transformation was provided recently by Downward and coworkers [162] . They generated mice with a mutant PI3KCA that carried substitutions in amino acids (Thr208 and Lys227) that are essential for its interaction with Ras. Cells from these mice show proliferative defects and selective disruption of signaling from growth factors to PI3K. They are highly resistant to endogenous Ras oncogene-induced tumorigenesis. The interaction of Ras with p110 is thus required in vivo for certain normal growth factor signaling and for Ras-driven tumor formation [162] .
However, recent data from mouse models suggest that PI3K inhibitors efficiently block PI3K mutant-dependent lung tumors, but not tumors induced by oncogenic Ras [155] . At the same time, combined treatment with PI3K and MEK inhibitors efficiently blocks ras-dependent tumors. These data are consistent with those of Yu et al. [163] , which demonstrated that PI3K inhibition resistance in cells is mainly contingent on MEK pathway activation.
THERAPEUTIC IMPLICATIONS
Clearly, all the evidence indicates that the PTEN/PI3K/AKT pathway is a promising target for cancer chemotherapy. Indeed, many companies and academic laboratories have initiated a variety of approaches to inhibit the pathway at different points. Essentially PI3Ks, PDK1, AKT and mTOR are heavily targeted for therapy in different ways. These proteins are kinases and very "druggable" targets a priori, and, according to the "addiction hypothesis", cancer cells with the activated pathway will be more dependent upon this pathway for their survival. Therefore, proper diagnosis of tumors with an activated PI3K pathway is pre-requisite for the use of the targeted therapies described.
The most direct of the therapeutic approaches outlined would be to target the p110 subunit itself. The PI3K inhibitors LY294002 and wortmannin, both targeting the catalytic site of p110, have been used as research tools to elucidate the value of PI3K as therapeutic target. Wortmannin is an irreversible inhibitor that forms a covalent bond in the ATP-binding cleft of the kinase. Wortmannin inhibits the enzymatic activity of PI3K in the nanomolecular range but has non-specific effects against other kinases [164] . LY294002 is a competitive inhibitor effective in the low micromolar range identified by optimization of the phytochemical quercetin. LY294002 also has a broad activity profile and did not pass to clinical trials due to its high unfavorable pharmacokinetic properties and toxicity. Besides many derivatives of these compounds, screenings for other small-molecule inhibitors of the catalytic ATP-binding pocket appear to be practical to identify new PI3K inhibitors. Thus, many imidazopyridines, pyridopyrimidines, quinazolyne derivatives, thiazoles, azolepyrimidine derivatives and other chemotypes have been reported to inhibit PI3K activity [164] .
Currently, many small molecules that are partially selective for different types of PI3Ks have been described for inflammation, thrombosis or chemotherapy, but none is specific for p110 . It seems that inhibitors of P110 or p110 are easier to separate than those specific for p110 or . The major non-target proteins affected by these compounds appear to be DNA-PK and mTOR [165] [166] [167] . Some pan PI3K inhibitors have been reported as nontoxic, with notable exceptions, suggesting that isoform specificity is non-essential. Furthermore, glucose metabolism alterations described in p110 kinase-dead mice have been described as being normalized after a few days in response to PI3K inhibitors. p110 , however, seems to be necessary for mammalian development. Mice deficient in p110 showed accelerated heart failure in response to dilated or hypertrophic cardiomyopathy. These results help explain the association of cardiomyopathy in patients undergoing treatment with tyrosine kinase inhibitors, and they raise concerns surrounding the use of p110 inhibitors in cancer patients with high cardiovascular risk [168] . Therefore, the extent to which PI3K inhibition is tolerated in human adults is not clear. Several PI3K inhibitors, all of them ATP competitive, entered clinical trials during 2008 [169] . They mostly show Pan-PI3K activity but are very specific towards other kinases tested. Several of these inhibitors are reported to also inhibit mTOR over similar range effective for PI3Ks. It has also been reported that dual PI3K/mTOR inhibition is more efficacious than PI3K inhibition alone [171] . Results from phase I clinical trials show that some of these inhibitors do not present major toxicity issues.
The value of PDK1 as target is mainly due to its ability to phosphorylate AKT. UCN-01 is a non-specific staurosporine analog that inhibits PDK1 at low nanomolar range [170] . UCN-01 is in clinical trials both as a single agent or in combination with other therapies. Other staurosporine and maleimide derivatives have been reported to inhibit PDK1 activity. The bottleneck is to discriminate among specific inhibitors given the similarity among members of the AGC family. The solution of the X-ray structure of PKA, AKT and PDK1 bound to ATP, ATP analogs or kinase inhibitors should facilitate the design of more specific and less toxic compounds.
Some celecoxib derivatives have been modified to maximize PDK1 inhibition with minimum effect to COX2 [171] . These inhibitors are active against different tumor cell lines, but they have a PDK1-independent activity that contributes to their antineoplastic effects [172] .
Two methods have been followed to identify new AKT inhibitors. By high-throughput screening, some inhibitors such as API2, API-59CJ-Ome, A443654 and canthine, alkaloid analogs were identified. These compounds inhibit cell growth in vitro and in vivo, stimulating apoptosis in xenografts with high AKT activity [173] . Isoform-specific AKT inhibitors were identified from canthine analogs in the micromolar range [174] [175] [176] . Treatment with AKT1 or AKT2 inhibitors sensitizes cells to chemotherapy, but maximum sensitization is obtained with dual AKT1/2 inhibitors [177] . The use of isoform-specific inhibition might reduce toxicity. On the other hand, modification of previously known kinase inhibitors such as staurosporine, the PKA inhibitor H-89 or other AGC-inhibitors has been undertaken with an eye toward the development of AKT-specific inhibitors. The identification of AKT inhibitors that are selective against other members of the AGCkinases is significantly complicated due to the high homology shared among the different catalytic domains.
Alternative approaches to block AKT have been explored. D-3-deoxy-phosphatidyl-myoinositol analogues, which cannot be phosphorylated by PI3K, have been designed and synthesized to interact with PH domains and disrupt activation of AKT. These compounds bind the PH domain of AKT, thus blocking the translocation of the protein and preventing its activation. Some of these compounds have been reported to inhibit proliferation of tumor cells at low micromolar doses (reviewed in [164] ). Another phospholipid, perifosine, interferes with the activation and phosphorylation of AKT in cells [178] . It has been suggested that perifosine interferes with the association of the AKT PH domain with PIP3, thus blocking membrane localization of the protein.
Perifosine is currently in phase II clinical trials for prostate, head and neck, breast, and pancreatic cancers and melanomas and sarcomas.
Since AKT might be regulated by DNA-PK and calcium, inhibitors of PI3K could cooperate with inhibitors of the DNA damage pathway or calcium agonists. This hypothesis, however, has to be further explored.
mTOR is an S/T kinase activated by AKT, which in turn might be also phosphorylated and activated by mTOR (in the mTORC2, mTOR/RICTOR complex). mTOR controls protein synthesis, angiogenesis and cell cycle progression and functions as a master switch between catabolic and anabolic metabolism. Inhibitors of mTOR constitute the most developed class of inhibitors of the PTEN/PI3K/AKT pathway. The mTOR inhibitor rapamycin has been approved as immunosuppressant, but several analogs have been developed as anticancer drugs [173] . CCI-779, RAD001 and AP23573 have shown potent activity as single agents or in combination with cytotoxic agents [179] . Most rapamycin analogs frequently induce cytostatic responses; it has therefore been suggested that combination with cytotoxic agents or radiation might enhance its antitumor activity. Nevertheless, the fact that rapamycin analogs do not inhibit the mTORC2 complex and how their antitumor responses compare to full inhibition of mTOR (mTORC1 and mTORC2) has not yet been well studied [180] .
To further enhance the effects of pathway inhibition, it might be useful to target the pathway at several points. For example, PDK1 can regulate translation independently of AKT by directly phosphorylating and activating a downstream effector of mTOR, S6K. In addition, mTOR can phosphorylate AKT in a positive feedback loop. Therefore, attacking the pathway at different points might enhance anti-neoplastic effects. This can be achieved by combining different drugs or compounds with combined specificities. Indeed, mTOR itself is a member of PI3K family of kinases, and there exist compounds that target both p110 and mTOR with good results in preclinical models [166, 167] .
Activation of PI3K pathway confers lapatinib resistance in vitro and in vivo. PI3K inhibition abrogated lapatinib resistance [181] [182]. PI3K pathway activation also mediates the resistance to imanitib in a subset of ALL. Furthermore, inhibitors of PI3K/AKT pathway greatly reduced BCR-ABL mediated transformation in vivo, suggesting that the AKT pathway mediates BCR-ABL leukemogenesis [183] . It is possible that the PI3K/AKT pathway mediates a great variety of responses to different treatments, either by direct involvement in the pathway or by control of the apoptotic pathway elicited by the treatment. In the former, advanced prostate cancers coordinately or alternatively express high levels of AKT/mTOR and MEK signaling effectors, and targeting these pathways inhibits hormone refractory prostate cancer in mouse models [184] . However, synergism observed between PI3K inhibitors and gemcitabine treatments is due to inhibition of antiapoptotic mechanisms (Bax translocation to mitochondria) induced by the PI3K pathway [185, 186] .
Besides direct inhibition of the PI3K pathway, numerous current therapies decrease AKT activity as byproduct of its inhibitory activity ( Table 1) . In many of these treatments, the extent of activity attributed to the decreases in AKT activity is not fully known. These interconnections might explain the synergism observed between PI3K inhibition and other chemotherapy agents observed in vitro and in vivo, further outlining the essential role of the AKT/PKB pathway in responses to anticancer therapy. Gleevec CML-BC, K562 [190, 191] Topotecan A549 [192] FTI-277 NIH3T3-AKT transformed [193] Histone deacetylase inhibitors ras-10T cells [194] 
